3rd Quarter - Report

BROWN RUDNICK LLP for HOSPIRA, INC.

Period 3rd Quarter 2012 Filed Oct 17, 2012 Signed by Henry W Menn III - Principal

Official filing
Firm
BROWN RUDNICK LLP
Client
HOSPIRA, INC.
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011; P.L. 111-14 - Patient Protection and Affordable Health Care Act provisions relating to biosimilar products; S. 2295 - Patient Safety and Generic Labeling Improvement Act

LobbyistCovered position, as disclosed
LISA LAYMAN SPA, Sen Stabenow(05-07)
HENRY W MENN Min SD & Counsel, Cmte on Vet Affairs (04)

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 2295 (112th), H.R. 3026 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.